Rituximab in the treatment of multiple sclerosis. Experience of a tertiary care hospital in Mexico

被引:0
|
作者
Castro-Macias, Jaime I. [1 ]
Rodriguez-Jimenez, Jose C. [2 ]
Mena-Novoa, Andres [3 ]
机构
[1] Hosp Reg Alta Especialidad Bajio, Serv Neurociencias, Leon, Mexico
[2] Hosp Reg Alta Especialidad Bajio, Serv Med Interna, Leon, Mexico
[3] Univ Guanajuato Leon, Dept Med & Nutr, Leon, Guanajuato, Mexico
来源
GACETA MEDICA DE MEXICO | 2023年 / 159卷 / 03期
关键词
Disability; Multiple sclerosis; Relapsing-remitting; Rituximab; SAFETY;
D O I
10.24875/GMM.23000014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multiple sclerosis is a chronic, autoimmune, degenerative disease. Therapies targeting B-cells have been shown to be effective in its treatment; however, there are few studies evaluating their efficacy in the Mexican population. Objective: To evaluate the clinical impact of rituximab in patients with newly-diagnosed relapsing-remitting multiple sclerosis (RRMS). Material and methods: Real life, descriptive study, in which rituximab was evaluated as treatment for RRMS over a 24-month period. Pre-and post-treatment clinical variables were analyzed; a comparison was made between treatment-naive and non -treatment-naive patients. Results: Twenty-eight patients with RRMS were included. Mean age at diagnosis was 30.7 years, and 22 patients were treatment-naive (78.5 %). After 24 months, there was a mean reduction of 1.8 points in the EDSS scale and a decrease in the number of active lesions on magnetic resonance imaging; a significant difference in both variables could be established (p < 0.05). However, the logistic regression model did not show a relationship between the variables for achiev-ing NEDA-3 criteria. No serious adverse events were observed. Conclusions: Treatment with rituximab resulted in significant clinical and radiological improvement in treatment-naive and non-treatment-naive Mexican patients with RRMS.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [21] Pathophysiology and treatment of fatigue in multiple sclerosis.
    Boërio, D
    Lefaucheur, JP
    Hogrel, JY
    Créange, A
    REVUE NEUROLOGIQUE, 2006, 162 (03) : 311 - 320
  • [22] Rituximab in multiple sclerosis: real world experience from three tertiary care MS centers from southern India
    Mathew, T.
    Baptist, A. A.
    Kamath, V.
    Murgod, U.
    Therambil, M.
    Shaji, A.
    Nadig, R.
    D'Souza, D.
    Avati, A.
    Badachi, S.
    Awati, A.
    Thomas, K.
    Sarma, G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 751 - 751
  • [23] Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
    Zecca, Chiara
    Bovis, Francesca
    Novi, Giovanni
    Capobianco, Marco
    Lanzillo, Roberta
    Frau, Jessica
    Repice, Anna Maria
    Hakiki, Bahia
    Realmuto, Sabrina
    Bonavita, Simona
    Curti, Erica
    Brambilla, Laura
    Mataluni, Giorgia
    Cavalla, Paola
    Di Sapio, Alessia
    Signoriello, Elisabetta
    Barone, Stefania
    Maniscalco, Giorgia T.
    Maietta, Ilaria
    Maraffi, Isabella
    Boffa, Giacomo
    Malucchi, Simona
    Nozzolillo, Agostino
    Coghe, Giancarlo
    Mechi, Claudia
    Salemi, Giuseppe
    Gallo, Antonio
    Sacco, Rosaria
    Cellerino, Maria
    Malentacchi, Maria
    De Angelis, Marcello
    Lorefice, Lorena
    Magnani, Eliana
    Prestipino, Elio
    Sperli, Francesca
    Morra, Vincenzo Brescia
    Fenu, Giuseppe
    Barilaro, Alessandro
    Abbadessa, Gianmarco
    Signori, Alessio
    Granella, Franco
    Amato, Maria Pia
    Uccelli, Antonio
    Gobbi, Claudio
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (12) : 1519 - 1531
  • [24] EXPERIENCE WITH THE USE OF RITUXIMAB FOR THE TREATMENT OF SYSTEMIC AUTOIMMUNE DISEASES (SAD) IN A TERTIARY HOSPITAL
    Sandez Montagut, Victor Manuel
    Blanco Alba, David
    Lopez Morales, Jose Ramon
    Nieto Garcia, Francisco Javier
    Rodriguez Suarez, Santiago
    Garcia Morillo, Salvador
    Garcia Hernandez, Francisco Jose
    Andreu Alvarez, Juan
    Martin-Garrido, Isabel
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1705 - 1705
  • [25] Rituximab in multiple sclerosis at general hospital level
    Hellgren, Johan
    Risedal, Anette
    Kallen, Kristina
    ACTA NEUROLOGICA SCANDINAVICA, 2020, 141 (06): : 491 - 499
  • [26] RESPONSE OF THE MODIFIED RODNAN SCALE WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE TREATMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS. EXPERIENCE IN PANAMA
    Perez Acuna, R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S42 - S42
  • [27] Multimodal complex treatment in multiple sclerosis. Influence on motor performance and need of care
    Ecker, D.
    Mauch, E.
    Sabolek, M.
    NERVENARZT, 2013, 84 (02): : 197 - 201
  • [28] Combined treatment of multiple sclerosis.: A case report
    Fonseca, A
    Noda, M
    González, I
    Gámez, O
    Montoya, A
    Daudinot, B
    REVISTA DE NEUROLOGIA, 2001, 32 (10) : 996 - 998
  • [29] Multiple Sclerosis. Early Start and consequent Treatment
    Setton, Juergen
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2012, 80 (09) : 551 - 551
  • [30] Targeting Fcgamma receptors in the treatment of multiple sclerosis.
    Schaefer, Beatrix
    Pellkofer, Hannah
    Breithoupt, Constanze
    Huber, Robert
    Jacob, Uwe
    CLINICAL IMMUNOLOGY, 2006, 119 : S115 - S116